M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Journal ArticleDOI
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Michael S. Gordon,Kim Margolin,M. Talpaz,George W. Sledge,E. Holmgren,R. Benjamin,Susan Stalter,S. Shak,Daniel C. Adelman +8 more
TL;DR: Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies.
Journal ArticleDOI
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard,Michael S. Gordon,Sunil Sharma,Saeed Rafii,Zev A. Wainberg,Jason J. Luke,Tyler J. Curiel,Gerardo Colon-Otero,Omid Hamid,Rachel E. Sanborn,Peter H. O'Donnell,Alexandra Drakaki,Winston Tan,John Kurland,Marlon Rebelatto,Xiaoping Jin,John A. Blake-Haskins,Ashok Kumar Gupta,Neil H. Segal +18 more
TL;DR: Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, many of whom were heavily pretreated.
Journal Article
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Michael B. Atkins,Michael J. Robertson,Michael S. Gordon,Michael T. Lotze,Michelle DeCoste,Jon S. Dubois,Jerome Ritz,Alan B. Sandler,Howard Edington,Pamela D. Garzone,James W. Mier,Christine Canning,Linda A. Battiato,Hideaki Tahara,Matthew L. Sherman +14 more
TL;DR: A Phase I dose escalation trial of recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects as discussed by the authors.
Journal ArticleDOI
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Gerald S. Falchook,Karl D. Lewis,Jeffrey R. Infante,Michael S. Gordon,Nicholas J. Vogelzang,Douglas J. DeMarini,Peng Sun,Christopher Moy,Stephen Szabo,Lori T Roadcap,Vijay Gopal Reddy Peddareddigari,Peter F. Lebowitz,Ngocdiep T. Le,Howard A. Burris,Wells A. Messersmith,Peter J. O'Dwyer,Kevin B. Kim,Keith T. Flaherty,Johanna C. Bendell,Rene Gonzalez,Razelle Kurzrock,Leslie A. Fecher +21 more
TL;DR: The data show substantial clinical activity of trametinib in melanoma and suggest that MEK is a valid therapeutic target, and differences in response rates according to mutations indicate the importance of mutational analyses in the future.